Literature DB >> 11488062

CD56+/CD4+ lymphomas and leukemias are morphologically, immunophenotypically, cytogenetically, and clinically diverse.

C K Rakozy1, A N Mohamed, T D Vo, G Khatib, P M Long, D Eilender, M Palutke.   

Abstract

CD56, a neural adhesion molecule, is a marker of natural killer (NK) lymphocytes as well as a subgroup of CD8+ T cells. Normal lymphocytes with a CD56/CD4 phenotype are scarce. Physiologic increases may occur in patients with immunosuppression, chronic inflammation, and autoimmune disorders. We report 4 cases of lymphomas/leukemias with the unusual CD56/CD4 phenotype. Two were of T-cell and 2 of true NK-cell origin. The T-cell lymphomas had large granular lymphocyte morphologic features and splenomegaly. One patients had a benign course; the other died within months of the leukemia diagnosis. The 2 NK cell lymphomas had blastic morphologic features, initially involved skin, and had a very aggressive clinical course; 1 patient died of acute leukemia, and 1 had recurrence after bone marrow transplantation. Cytogenetic analyses did not show a consistent pattern of abnormalities. The NK lymphoma with acute leukemia had a t(2;5) but was CD30- and anaplastic lymphoma kinase negative. Although CD56+/CD4+ lymphomas/leukemias are a heterogeneous group, there may be a distinct subgroup of NK lymphoblastoid lymphomas of the skin, judging from our cases, as well as those previously reported.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11488062     DOI: 10.1309/FMYW-UL3G-1D7J-ECQF

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  3 in total

1.  CD4+CD56+ lineage negative hematopoietic neoplasm: so called blastic NK cell lymphoma.

Authors:  Yoonjung Kim; Mi Seon Kang; Chan Whan Kim; Rohyun Sung; Young H Ko
Journal:  J Korean Med Sci       Date:  2005-04       Impact factor: 2.153

2.  Simultaneous deletion of 3'ETV6 and 5'EWSR1 genes in blastic plasmacytoid dendritic cell neoplasm: case report and literature review.

Authors:  Zhenya Tang; Guilin Tang; Sa A Wang; Xinyan Lu; Ken H Young; Carlos E Bueso-Ramos; Yesid Alvarado; L Jeffrey Medeiros; Joseph D Khoury
Journal:  Mol Cytogenet       Date:  2016-02-27       Impact factor: 2.009

Review 3.  What is CD4+CD56+ malignancy and how should it be treated?

Authors:  P Reimer; T Rüdiger; D Kraemer; V Kunzmann; F Weissinger; A Zettl; H Konrad Müller-Hermelink; M Wilhelm
Journal:  Bone Marrow Transplant       Date:  2003-10       Impact factor: 5.483

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.